NCT05026983 2026-04-16
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05985954 2026-03-12
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT04903119 2026-02-13
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Phase 1 Recruiting
NCT03803553 2025-12-23
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT06887088 2025-10-01
ENCEFALO
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT05706779 2025-09-02
NEORAF
Federation Francophone de Cancerologie Digestive
Phase 2 Recruiting
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT06640166 2025-02-12
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Recruiting
NCT06411600 2024-11-08
BRAVE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting